Newsmeme!
Discover News you didn't know existed
Reportlinker.com announces that a new market research report is available in its catalogue:
Vancouver, BC, February 9, 2010--(T-Net)--Tekmira Pharmaceuticals Corporation (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics and proprietary delivery technology, announced today its 2010 milestones, which include the progress of multiple RNAi product candidates into clinical development by Tekmira and its partners.
Five SNALP Based RNAi Products Anticipated to be in Clinical Development in 2010
VANCOUVER, BRITISH COLUMBIA--(Marketwire - 02/09/10) - Tekmira Pharmaceuticals Corporation (TSX: TKM - News ), a leading developer of RNA interference (RNAi) therapeutics and proprietary delivery technology, announced today its 2010 milestones, which include the progress of multiple RNAi product candidates into clinical development by Tekmira and its partners. Dr. Mark J. Murray, Tekmira's ...
CONCORD, Calif.----Cerus Corporation announced today that it has entered into a collaborative agreement with France's national transfusion service, the Etablissement Français du Sang , for the development of the company's INTERCEPT Blood System for red blood cells.
Marc Dunoyer, president of Asia Pacific and chairman of Japan at GSK, is expected to lead the new operation, working closely with Patrick Vallance, senior vice president of drug discovery.
A new functional supplement using Cognizin® Citicoline from Kyowa Hakko USA in the patent-pending formulation has been introduced by Nawgan Products, LLC of Chesterfield, MO. Nawgan Berry is the first functional health liquid supplement that pre-blends Cognizin® with other ingredients to enhance cognitive function
Cerus Corporation (NASDAQ:CERS) announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating ...
CONCORD, Calif.----Cerus Corporation announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated cells continued to circulate 24 hours following transfusion.
Qiagen N.V. / QIAGEN Reports Strong Fourth Quarter and Fiscal 2009 Results processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |